Study faults research linking hormone therapy to cancer

January 17, 2012

A landmark investigation which found that hormone treatment for the menopause boosts the risk of breast cancer is riddled with flaws, a new study published on Monday alleges.

The so-called Million Women Study (MWS) unleashed headlines when it was first published in 2003.

Based on questionnaires returned by more than a million post-menopausal women in Britain, it said (HRT) led to a rise in breast-cancer incidence.

Its estimate caused a wave of anxiety -- and much confusion -- among regulators and doctors and among women using HRT.

HRT uses the female hormones oestrogen or progestogen, sometimes combined, to ease such as hot flushes, loss of sex drive and .

Updates of the MWS have finetuned the perceived risk. The MWS website says there is an increased of 30 percent in oestrogen-only treatment, and a twofold risk in oestrogen-progestogen therapy, compared with women who do not take these drugs.

The risk increases the longer a woman uses HRT, but drops to normal level within five years after stopping use, the MWS says.

But an assessment published on Monday in the Journal of and says the MWS's design has so many problems that a safe conclusion cannot be drawn.

"HRT may or may not increase the risk of breast cancer, but the MWS did not establish that it does," the paper says bluntly.

Among half a dozen points, the authors say cancers detected within a few months of the study's start would have already been present when the women were enrolled.

But these cases were not stripped out of the cancer count, it says.

The review also points to "detection bias" through the choice of participants.

The volunteers were taking part in a programme when they were invited to join the study.

They would thus have already known about and suspect that point to breast cancer. As a result, the MWS found a 40-percent higher incidence of breast cancer among its volunteers -- regardless of whether they used hormone therapy or not -- than in the population at large.

The paper also notes that breast cancers typically take many years to develop. It was thus "biologically implausible" that so many would have cropped up within a year or two of enrolment in the study, as the MWS maintained.

"The name 'Million Women Study' implies an authority beyond criticism or refutation," say the authors, led by Samuel Shapiro, a professor of public health at the University of Cape Town, South Africa.

"Yet the validity of any study is dependent on the quality of its design, execution, analysis and interpretation. Size alone does not guarantee that the findings are reliable."

In an email to AFP, the leaders of the MWS rebutted the criticism, saying that more than 20 studies had replicated its findings and a decline in the use of HRT had led to a fall in cases of breast cancer.

"Hormone-sensitive cancers are still three times as common in HRT users as in non-users or ex-users," said Richard Peto, a professor of statistics and epidemiology at Oxford University.

Independent commentator Anne Gombel, a French professor who is a member of the International Menopause Society, said a complex picture about breast cancer was emerging.

Breast density, alcohol and obesity, and not just HRT are now emerging as risk factors that should be taken into account, and not just HRT, said Gombel.

"HRT does not carry the same risk and benefit for each woman; some women will have increased risks, some will have only benefits, and this also applies to ."

Explore further: Women should still be concerned about hormone replacement therapy, researchers say

Related Stories

Women should still be concerned about hormone replacement therapy, researchers say

December 21, 2011
McMaster University researchers have found consistent evidence that use of hormone replacement therapy (HRT) is associated with breast cancer globally. This study comes at a time when more women are again asking for this ...

Breast cancer type linked to paternal cancer

November 28, 2011
The risk of breast cancer is increased by genetic and lifestyle factors such as the inherited BRCA2 gene, age of having first child, or use of hormone replacement therapy (HRT). New research published in BioMed Central's ...

Women with BRCA mutations can take hormone-replacement therapy safely after ovary removal

June 1, 2011
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.